QIAGEN N.V. announced that China’s State Food and Drug Administration (SFDA) has approved QIAGEN’s careHPV Test and instrument platform. The careHPV Test is the first molecular diagnostic to screen ...
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that China's State Food and Drug Administration (SFDA) has approved QIAGEN's careHPV Test and instrument platform. The careHPV ...
Qiagen's careHPV for use in areas with limited healthcare infrastructure--Courtesy of PATH Dutch molecular diagnostics conglomerate Qiagen ($QGEN) launched its new ...
Qiagen’s careHPV Test and instrument platform has been approved by China’s State Food and Drug Administration (SFDA). According to the company, the careHPV Test is the first molecular diagnostic to ...
QIAGEN N.V. today announced the commercial launch in India of its careHPV ™ Test, the only molecular diagnostic for high-risk human papillomavirus (HPV) designed to screen women in settings with ...
Qiagen NV announced a milestone with the delivery of more than 75 million digene HPV tests worldwide - the gold standard in screening women for human papillomavirus, which is the primary cause of ...
Global launch of CE marked careHPV and new CE marked self-collection claim for HPV sampling device help to provide HPV screening for women most in need QIAGEN N.V. today announced its latest ...
Qiagen's digene HC2 HPV DNA Test--Courtesy of Qiagen Molecular diagnostics company Qiagen ($QGEN) will invest $10 million to build out manufacturing capabilities at ...
We evaluated the performance of primary high-risk human papillomavirus (hrHPV) testing by hybrid capture 2 (HC2) with different thresholds for positivity, in comparison with conventional cytology. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results